# Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

> **NCT04893148** · PHASE4 · UNKNOWN · sponsor: **Chungbuk National University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Glucose, High Blood

## Interventions

- **DRUG:** IGlarLixi
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT04893148
- **Lead sponsor:** Chungbuk National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-26
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04893148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04893148, "Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04893148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*